The University of Maryland School of Medicine is one of three study sites participating in a human safety trial of an investigational Zika virus vaccine.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced the trial on Aug. 2. The study will test the experimental vaccine’s safety and ability to generate an immune system response in 80 healthy participants, aged 18-35 in Baltimore, at the NIH Clinical Center in Bethesda, Md., and at Emory University in Atlanta. The vaccine candidate was developed by NIAID scientists at the agency’s Vaccine Research Center earlier this year.
Read more about the vaccine study at NIAID.NIH.gov.